Month: August 2024

Total Revenue up 24% YoY to $16.2 million Adjusted EBITDA ⁽²⁾ up 41% YoY to $4.2 million Annual Recurring Revenue (ARR) ⁽¹⁻²⁾ up 25% YoY to $51.3 million TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management’s Discussion and Analysis report for the three and six months ended June 30, 2024, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com. “We are pleased to report a strong second quarter in 2024, marked by significant organic growth and strategic advancements,” stated Dan Matlow, CEO of VitalHub. “With our second quarter revenue reaching $16.2 million, a 24% increase from the previous year,...

MONTRÉAL, Aug. 08, 2024 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the first quarter of fiscal 2025, which ended on June 30, 2024. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS). “We delivered a very good first quarter with strong revenue and adjusted EBITDA1 growth and solid cash generation. More importantly, we are clearly seeing the benefits from the bold actions we have taken over the past few years. Capital projects in the US are now up and running, while other expansion and modernization efforts around the globe remain right on track. The dairy commodity environment in the US also began to stabilize...

TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to ProceedAbstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH)SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended June 30, 2024, and provided a corporate update. “We are pleased that our triplet protocol of tuspetinib with venetoclax and azacitidine (TUS+VEN+AZA) has been allowed to proceed at the 40 mg dose...

Irvine, Aug. 08, 2024 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) yesterday filed with the Securities and Exchange Commission (the “Commission”) its quarterly report on Form 10-Q announcing financial results for the quarter ended June 30, 2024. Quarterly Results The Company reported total revenue of $1,569,954 for the quarter ended June 30, 2024, compared with total revenue of $1,324,053 for the quarter ended June 30, 2023. The Company reported income from operations of $191,995 for the quarter ended June 30, 2024, compared to income from operations of $145,118 during the quarter ended June 30, 2023. The Company realized net income of $215,556 or $0.02 per share on a basic and fully diluted basis for the second quarter of 2024, compared to net income of $176,427 or $0.01 per share...

Selected HighlightsSecond quarter Operating EBITDA* of $30.4 million and net loss of $67.6 million Strengthened pulp markets drive improvement in operating cash flows and liquidity Quarterly cash dividend of $0.075 per shareNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq: MERC) today reported second quarter 2024 Operating EBITDA of $30.4 million, an increase from negative Operating EBITDA of $68.7 million in the same quarter of 2023 and a decrease from Operating EBITDA of $63.6 million in the first quarter of 2024. In the second quarter of 2024, net loss was $67.6 million ($1.01 per share), which included a non-cash impairment of $34.3 million ($0.51 per share) against goodwill related to the Torgau facility, compared to a net loss of $98.3 million ($1.48 per share) in the second quarter of 2023...